Biotechs Hit Bottom and Bounce Back — Twice
August 18, 2022
Nierengarten, David
Low Cost of Capital Sets Stage for Uptick in Biotech M&A
March 18, 2021
Nierengarten, David
Seeing a Bifurcation of Therapeutic Focus in the Oncology Space
September 30, 2020
Nierengarten, David
Clinical Data and M&A Serve as Catalysts in 2019
March 22, 2019
Roy, Soumit
Relatively Healthy Valuations for Development-Stage Companies
October 02, 2018
Nierengarten, David
